Drug intelligence / Profile preview

LT-010391

Development stage: Phase 1
Lead developer: Leadingtac
Modality: Small Molecules
Administration: Oral

Overview

LT-010391 is an orally bioavailable small molecule inhibitor specifically targeting the KRAS G12D mutation. Developed by Leadingtac Pharmaceutical (Shaoxing) Co., Ltd., it is designed to treat advanced solid tumors harboring the KRAS G12D mutation, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). The KRAS G12D mutation is a frequent oncogenic driver in these cancers, and LT-010391 aims to inhibit the constitutively active signaling associated with this mutant protein. The drug is currently undergoing Phase I clinical evaluation to determine its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced malignancies.

Targets

KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on LT-010391.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LT-010391.

Explore the full profile